RUBIDAZONE VS ADRIAMYCIN - EVALUATION OF THEIR DIFFERENTIAL TOXICITY IN SPLEEN COLONY ASSAY SYSTEM

被引：14

作者：

ALBERTS, DS ^{[1
]}

VANDAALENWETTERS, T ^{[1
]}

机构：

[1] UNIV ARIZONA,COLL MED,DEPT MED,HEMATOL ONCOL SECT,TUCSON,AZ 85724

来源：

关键词：

D O I：

10.1038/bjc.1976.123

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：64 / 68

页数：5

共 15 条

[1] BERNARD J, 1972, NOUV PRESSE MED, V1, P2149
[2] ADRIAMYCIN - NEW ANTICANCER DRUG WITH SIGNIFICANT CLINICAL ACTIVITY
BLUM, RH
CARTER, SK
[J]. ANNALS OF INTERNAL MEDICINE, 1974, 80 (02) : 249 - 259
[3] CHAUVERGNE J, 1973, BORDEAUX MED, V12, P1757
[4] COURTS EP, 1972, CANCER CHEMOTHER REP, V56, P237
[5] HARRIS JW, 1973, CANCER RES, V33, P1780
[6] TREATMENT OF ACUTE MYELOBLASTIC LEUKEMIA WITH RP 22050
JACQUILLAT, C
IZRAEL, V
SCHAISON, G
WEIL, M
BOIRON, M
BERNARD, J
GEMON, MF
[J]. BMJ-BRITISH MEDICAL JOURNAL, 1972, 4 (5838): : 468 - +
[7] JACQUILLAT C, 1974, JUL ANTHR ANT M NAT
[8] JOHNSON R, 1974, JUL ANTHR ANT M NAT
[9] KLENER P, 1973, NEOPLASMA, V20, P87
[10] LEFRAK EA, 1973, CANCER-AM CANCER SOC, V32, P302, DOI 10.1002/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO